ArticleArchives of microbiology2025
In vitro efficacy of bovine lactoferrin against bovine viral diarrhea virus.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bovine Lactoferrin Inhibits Pseudorabies Virus Attachment Through Blockade of Glycoprotein C-Heparan Sulfate Interaction.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bovine viral diarrhea virus (BVDV) infection represents a significant economic challenge to the global cattle industry, leading to considerable losses in productivity and increased management costs. This underscores the urgent need for effective antiviral strategies to combat BVDV infection. In this study, we demonstrated that bovine lactoferrin (bLF), a multifunctional glycoprotein with known antimicrobial properties, exhibited potent inhibitory activity against BVDV infection. Importantly, the antiviral effect of bLF was not mediated by cytotoxicity towards host cells, indicating its safety for potential applications. Mechanistic investigations revealed that bLF did not interfere with viral RNA translation or replication, nor did it impair viral assembly or release. Instead, bLF effectively blocked BVDV infection during the early stages of the viral lifecycle, likely by competitively binding to cellular receptor molecules involved in viral entry. These findings identify bLF as a promising candidate for the development of antivirals targeting BVDV infection, offering a novel and effective approach to managing BVDV-associated diseases.
Indexed as
Identifiers
40261405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.